Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus

Endocrine

Volumn 47, Issue 3, 2014, Pages 962-964

  Okada, Kenta ^a   Kotani, Kazuhiko ^a   Yagyu, Hiroaki ^b   Ando, Akihiko ^a   Osuga, Jun ichi ^a   Ishibashi, Shun ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; LIRAGLUTIDE; MALONALDEHYDE; NATRIURETIC FACTOR; REACTIVE OXYGEN METABOLITE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; NATRIURETIC PEPTIDE TYPE C;

ADULT; CARDIOVASCULAR RISK; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; HEART PROTECTION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; TREATMENT DURATION; TREATMENT OUTCOME; AGED; ANALOGS AND DERIVATIVES; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; MIDDLE AGED;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, C-TYPE; OXIDATIVE STRESS;

EID: 84911960521     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0246-6     Document Type: Letter

References (16)

1. M.H. Davidson, Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist. Am. J. Cardiol. 110(9 Suppl), 43B–49B (2012)
2. E.R. Levin, D.G. Gardner, W.K. Samson, Natriuretic peptides. N. Engl. J. Med. 339, 321–328 (1998)
3. T.J. Wang, M.G. Larson, D. Levy, E.J. Benjamin, E.P. Leip, T. Omland, P.A. Wolf, R.S. Vasan, Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med. 350, 655–663 (2004)
4. A.C. Maritim, R.A. Sanders, J.B. Watkins 3rd, Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17, 24–38 (2003)
5. C. Vassalle, An easy and reliable automated method to estimate oxidative stress in the clinical setting. Methods Mol. Biol. 477, 31–39 (2008)
6. I.N. Migdalis, P. Triantafilou, E. Petridou, N. Varvarigos, V. Totolos, A. Rigopoulos, Lipid peroxides in type 2 diabetic patients with neuropathy. Res. Commun. Mol. Pathol. Pharmacol. 117–118, 5–12 (2005)
7. R. Sayın, M. Aslan, M.E. Kucukoglu, A. Luleci, M. Atmaca, R. Esen, H. Demir, Serum prolidase enzyme activity and oxidative stress levels in patients with diabetic neuropathy. Endocrine (2013). doi:10.1007/s12020-013-0136-3
8. K.B. Degn, C.B. Juhl, J. Sturis, G. Jakobsen, B. Brock, V. Chandramouli, J. Rungby, B.R. Landau, O. Schmitz, One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53, 1187–1194 (2004)
9. G. Díaz-Soto, D.A. de Luis, R. Conde-Vicente, O. Izaola-Jauregui, C. Ramos, E. Romero, Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with type 2 diabetes: a prospective study. Diabetes Res. Clin. Pract. (2014). doi:10.1016/j.diabres.2014.01.019
10. C.B. Giorda, E. Nada, B. Tartaglino, Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine (2014). doi:10.1007/s12020-014-0179-0
11. M.H. Noyan-Ashraf, M.A. Momen, K. Ban, A.M. Sadi, Y.Q. Zhou, A.M. Riazi, L.L. Baggio, R.M. Henkelman, M. Husain, D.J. Drucker, GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58, 975–983 (2009)
12. J.P. Courrèges, T. Vilsbøll, M. Zdravkovic, T. Le-Thi, T. Krarup, O. Schmitz, R. Verhoeven, I. Bugáñová, S. Madsbad, Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet. Med. 25, 1129–1131 (2008)
13. Y. Notsu, E. Fukuma, H. Shibata, J. Masuda, Y. Ishibashi, Evaluation of plasma brain natriuretic peptide concentration used by AIA-360. Jpn. J. Med. Pharm. Sci. 52, 397–402 (2004)
14. N. Mikhail, Effects of incretin-based therapy in patients with heart failure and myocardial infarction. Endocrine (2014). doi:10.1007/s12020-014-0175-4
15. C.J. Li, Q. Yu, P. Yu, T.L. Yu, Q.M. Zhang, S. Lu, D.M. Yu, Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc. Diabetol. (2014). doi:10.1186/1475-2840-13-36
16. G. Noberaseo, P. Odetti, D. Boeri, M. Maiello, L. Adezati, Malondialdehyde (MDA) level in diabetic subjects. Relationship with blood glucose and glycated hemoglobin. Biomed. Pharmacother. 45, 193–196 (1991)